Cargando…

Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial

OBJECTIVE: The BEACON CRC randomised controlled trial (NCT02928224) in BRAF-mutant metastatic colorectal cancer (mCRC) patients showed improved overall survival for the combination treatment of encorafenib (BRAF inhibitor) with cetuximab (EGFR inhibitor) compared with cetuximab with chemotherapy (FO...

Descripción completa

Detalles Bibliográficos
Autores principales: Trouiller, Jean-Baptiste, Macabeo, Bérengère, Poll, Andrew, Howard, Dan, Buckland, Andy, Sivignon, Marine, Clay, Emilie, Malka, David, Samalin, Emmanuelle, Toumi, Mondher, Laramée, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9680156/
https://www.ncbi.nlm.nih.gov/pubmed/36410812
http://dx.doi.org/10.1136/bmjopen-2022-063700
_version_ 1784834348842745856
author Trouiller, Jean-Baptiste
Macabeo, Bérengère
Poll, Andrew
Howard, Dan
Buckland, Andy
Sivignon, Marine
Clay, Emilie
Malka, David
Samalin, Emmanuelle
Toumi, Mondher
Laramée, Philippe
author_facet Trouiller, Jean-Baptiste
Macabeo, Bérengère
Poll, Andrew
Howard, Dan
Buckland, Andy
Sivignon, Marine
Clay, Emilie
Malka, David
Samalin, Emmanuelle
Toumi, Mondher
Laramée, Philippe
author_sort Trouiller, Jean-Baptiste
collection PubMed
description OBJECTIVE: The BEACON CRC randomised controlled trial (NCT02928224) in BRAF-mutant metastatic colorectal cancer (mCRC) patients showed improved overall survival for the combination treatment of encorafenib (BRAF inhibitor) with cetuximab (EGFR inhibitor) compared with cetuximab with chemotherapy (FOLFIRI (folinic acid, fluorouracil and irinotecan) or irinotecan). We aimed to evaluate the cost-effectiveness of encorafenib with cetuximab in adult patients with BRAF-mutant mCRC after prior systemic therapy, from the perspective of the French healthcare system. DESIGN: A partitioned survival analysis model was developed to assess the cost-effectiveness of encorafenib with cetuximab using data from BEACON CRC (encorafenib with cetuximab and cetuximab with FOLFIRI or irinotecan). For two further comparator treatments (FOLFIRI alone and bevacizumab with FOLFIRI), a systemic literature review identified appropriate clinical trial data for indirect comparison. Piecewise modelling extrapolation was used to fulfil a lifetime horizon in the model. A discount rate of 2.5% was used. Treatment-emergent adverse events ≥grade 3 with an incidence of ≥2% were included, as well as relative dose intensity and utility values. OUTCOME MEASURES: The effectiveness outcomes of the model were expressed in terms of incremental life years gained and incremental quality-adjusted life years (QALY) gained. The cost-effectiveness of encorafenib with cetuximab was assessed using the incremental cost-effectiveness ratio (ICER). Results were presented probabilistically to account for parametric uncertainty. Deterministic and scenario analyses were conducted. RESULTS: The ICER for encorafenib with cetuximab versus cetuximab with FOLFIRI or irinotecan, FOLFIRI alone and bevacizumab with FOLFIRI was €69 823/QALY, €70 421/QALY and €72 336/QALY, respectively. Encorafenib with cetuximab was considered cost-effective compared with the three comparators at a willingness to pay threshold of €90 000/QALY, with probabilities of being cost-effective of 89.8%, 98.2% and 86.4%, respectively. CONCLUSIONS: This analysis showed encorafenib with cetuximab to be a cost-effective treatment in mCRC patients with a BRAF V600E mutation.
format Online
Article
Text
id pubmed-9680156
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-96801562022-11-23 Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial Trouiller, Jean-Baptiste Macabeo, Bérengère Poll, Andrew Howard, Dan Buckland, Andy Sivignon, Marine Clay, Emilie Malka, David Samalin, Emmanuelle Toumi, Mondher Laramée, Philippe BMJ Open Health Economics OBJECTIVE: The BEACON CRC randomised controlled trial (NCT02928224) in BRAF-mutant metastatic colorectal cancer (mCRC) patients showed improved overall survival for the combination treatment of encorafenib (BRAF inhibitor) with cetuximab (EGFR inhibitor) compared with cetuximab with chemotherapy (FOLFIRI (folinic acid, fluorouracil and irinotecan) or irinotecan). We aimed to evaluate the cost-effectiveness of encorafenib with cetuximab in adult patients with BRAF-mutant mCRC after prior systemic therapy, from the perspective of the French healthcare system. DESIGN: A partitioned survival analysis model was developed to assess the cost-effectiveness of encorafenib with cetuximab using data from BEACON CRC (encorafenib with cetuximab and cetuximab with FOLFIRI or irinotecan). For two further comparator treatments (FOLFIRI alone and bevacizumab with FOLFIRI), a systemic literature review identified appropriate clinical trial data for indirect comparison. Piecewise modelling extrapolation was used to fulfil a lifetime horizon in the model. A discount rate of 2.5% was used. Treatment-emergent adverse events ≥grade 3 with an incidence of ≥2% were included, as well as relative dose intensity and utility values. OUTCOME MEASURES: The effectiveness outcomes of the model were expressed in terms of incremental life years gained and incremental quality-adjusted life years (QALY) gained. The cost-effectiveness of encorafenib with cetuximab was assessed using the incremental cost-effectiveness ratio (ICER). Results were presented probabilistically to account for parametric uncertainty. Deterministic and scenario analyses were conducted. RESULTS: The ICER for encorafenib with cetuximab versus cetuximab with FOLFIRI or irinotecan, FOLFIRI alone and bevacizumab with FOLFIRI was €69 823/QALY, €70 421/QALY and €72 336/QALY, respectively. Encorafenib with cetuximab was considered cost-effective compared with the three comparators at a willingness to pay threshold of €90 000/QALY, with probabilities of being cost-effective of 89.8%, 98.2% and 86.4%, respectively. CONCLUSIONS: This analysis showed encorafenib with cetuximab to be a cost-effective treatment in mCRC patients with a BRAF V600E mutation. BMJ Publishing Group 2022-11-21 /pmc/articles/PMC9680156/ /pubmed/36410812 http://dx.doi.org/10.1136/bmjopen-2022-063700 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Health Economics
Trouiller, Jean-Baptiste
Macabeo, Bérengère
Poll, Andrew
Howard, Dan
Buckland, Andy
Sivignon, Marine
Clay, Emilie
Malka, David
Samalin, Emmanuelle
Toumi, Mondher
Laramée, Philippe
Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial
title Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial
title_full Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial
title_fullStr Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial
title_full_unstemmed Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial
title_short Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial
title_sort economic evaluation of encorafenib with cetuximab in patients with braf v600e-mutant metastatic colorectal cancer in france: a cost-effectiveness analysis using data from the beacon crc randomised controlled trial
topic Health Economics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9680156/
https://www.ncbi.nlm.nih.gov/pubmed/36410812
http://dx.doi.org/10.1136/bmjopen-2022-063700
work_keys_str_mv AT trouillerjeanbaptiste economicevaluationofencorafenibwithcetuximabinpatientswithbrafv600emutantmetastaticcolorectalcancerinfranceacosteffectivenessanalysisusingdatafromthebeaconcrcrandomisedcontrolledtrial
AT macabeoberengere economicevaluationofencorafenibwithcetuximabinpatientswithbrafv600emutantmetastaticcolorectalcancerinfranceacosteffectivenessanalysisusingdatafromthebeaconcrcrandomisedcontrolledtrial
AT pollandrew economicevaluationofencorafenibwithcetuximabinpatientswithbrafv600emutantmetastaticcolorectalcancerinfranceacosteffectivenessanalysisusingdatafromthebeaconcrcrandomisedcontrolledtrial
AT howarddan economicevaluationofencorafenibwithcetuximabinpatientswithbrafv600emutantmetastaticcolorectalcancerinfranceacosteffectivenessanalysisusingdatafromthebeaconcrcrandomisedcontrolledtrial
AT bucklandandy economicevaluationofencorafenibwithcetuximabinpatientswithbrafv600emutantmetastaticcolorectalcancerinfranceacosteffectivenessanalysisusingdatafromthebeaconcrcrandomisedcontrolledtrial
AT sivignonmarine economicevaluationofencorafenibwithcetuximabinpatientswithbrafv600emutantmetastaticcolorectalcancerinfranceacosteffectivenessanalysisusingdatafromthebeaconcrcrandomisedcontrolledtrial
AT clayemilie economicevaluationofencorafenibwithcetuximabinpatientswithbrafv600emutantmetastaticcolorectalcancerinfranceacosteffectivenessanalysisusingdatafromthebeaconcrcrandomisedcontrolledtrial
AT malkadavid economicevaluationofencorafenibwithcetuximabinpatientswithbrafv600emutantmetastaticcolorectalcancerinfranceacosteffectivenessanalysisusingdatafromthebeaconcrcrandomisedcontrolledtrial
AT samalinemmanuelle economicevaluationofencorafenibwithcetuximabinpatientswithbrafv600emutantmetastaticcolorectalcancerinfranceacosteffectivenessanalysisusingdatafromthebeaconcrcrandomisedcontrolledtrial
AT toumimondher economicevaluationofencorafenibwithcetuximabinpatientswithbrafv600emutantmetastaticcolorectalcancerinfranceacosteffectivenessanalysisusingdatafromthebeaconcrcrandomisedcontrolledtrial
AT larameephilippe economicevaluationofencorafenibwithcetuximabinpatientswithbrafv600emutantmetastaticcolorectalcancerinfranceacosteffectivenessanalysisusingdatafromthebeaconcrcrandomisedcontrolledtrial